SUMMARY

INTRODUCTION
Cancer stem cells (CSC), which have been characterized with surface markers in tumors, possess the malignant capacities of self-renewal and pluripotency, thus initiating tumorigenesis and driving tumor progression (1) (2) (3) (4) . In human breast cancer, the CD44 + /ESA + /CD24 -/low cells have been tested as breast cancer stem cells (BCSCs), since they are able to differentiate into cells with diverse phenotypes and have tumorous pluripotency to generate mammary tumors and metastases in vivo (3, 5) . BCSCs, like other CSCs, give rise to tumor resistance to chemotherapy and radiation (6) (7) (8) . As a cause of tumor metastasis and recurrence, CSC is an adverse prognostic factor for cancer patients (9) (10) (11) and a critical target to eradicate cancers (12) (13) (14) (15) . CSCs are distinguished by loss of tissue homeostasis control and often display unlimited proliferation and growth from normal stem cells, even though both share the similar properties in self-renewal, pluripotency, and resistance to cytotoxins (2, 16) . Targeting CSCs pharmacologically for therapeutic purpose requires understanding by which mechanisms CSCs maintain their tumor behaviors.
Several cellular signals including Wnt, Notch and Hedgehog have been reported to be implicated in the self-renewal ability and pluripotency of normal stem cells in mammary gland development or remodeling, and of BCSCs in cancer pathogenesis (5, (16) (17) (18) (19) . It is not clear how BCSCs, like other CSCs, maintain tumor pluripotency without tissue homeostasis control. Glycosphingolipids (GSLs), particular globoseries GSLs, are common markers of undifferentiated embryonic stem cells (ESCs) (20) (21) (22) . As essential components of lipid rafts, particularly GSL-enriched microdomains (GEM) in plasma membrane, GSLs actively mediate cellular signals, gene regulation, and functions (23) (24) (25) (26) . GSLs may play a vital role in maintaining ESCs, as deletion of GSLs induces apoptosis of ESCs and stops embryo development in ugcg (encoding glucosylceramide synthase, GCS) knockout mouse (27) . GCS catalyzes ceramide glycosylation and is a limiting enzyme controlling the synthesis of GSLs (28, 29) . Enhanced ceramide glycosylation by GCS converts ceramide to GSLs, conferring multidrug resistance of cancer cells (30, 31) . It has been reported that GCS is overexpressed in metastatic breast tumors (32, 33) and inhibition of GCS decreases lung tumor metastasis (34) . These studies suggest that ceramide glycosylation by GCS is associated with CSC behaviors. We examined the correlation of ceramide glycosylation with BCSCs in drug resistance and tumorigenesis.
Cell viability assay-Cell viability was analyzed by quantification of ATP, an indicator of metabolically active cells using the CellTiter-Glo luminescent cell viability assay (Promega, Madison, WI), as described previously (38) . Briefly, cells (4,000 cells/well) were grown in 96-well plates with 10% FBS RPMI-1640 medium for 24 hr. MBO-asGCS was introduced into cells by Lipofectamine 2000 (vehicle control) in Opti-MEM reduced-serum medium for 4 hr incubation. Cells were then incubated with increasing concentrations of doxorubicin in 5% FBS medium for another 72 hr. Cell viability was determined by the measurement of luminescent ATP in a Synergy HT microplate reader (BioTek, Winooski, VT), following incubation with CellTiter-Glo reagent (Promega, Madison, WI).
Colony formation assay-Cells (10,000 cells/800 μl) were suspended in 10% FBS RPMI-1640 medium containing 0.2% agarose and overlaid onto 24 well plates containing a solidified bottom layer of 0.3% agarose (600 μl) in 10% RPMI-1640 medium. Once the top layer solidified, 600 μl of 10% FBS RPMI-1640 medium was placed on the top to keep wells moist. For MBOasGCS treatment, the cells were pretreated with MBO-asGCS as described above. In addition, the MBO-asGCS (200 nM) was added with the 0.2% agarose medium (top layer). Plates were incubated for 1 week until the colonies were visible. The cell numbers of colonies were determined by the measurement of luminescent ATP in a Synergy HT microplate reader, following incubation with CellTiter-Glo reagent for 30 min, at room temperature with gentle shaking.
Tumor sphere assay-It was performed as described previously with minor modification (39, 40) . Briefly, after sorting, BCSCs or CD44 -/CD24 -cells (5,000 cells/well) were plated in ultralow attachment 24-well plates (Corning, Lowell, MA) with DMEM-F12
(1:1) medium containing insulin (5 μg/ml), human basic fibroblast growth factor (10 ng/ml), human epidermal growth factor (20 ng/ml) and 0.4% bovine serum albumin (BSA). The BCSCs were treated with MBOasGCS (100 nM) for 7 days, and the medium was refreshed on day 4. The tumor spheres were observed and photomicrographed.
Cell sorting-Sorting was performed using magnetic beads (Dynabeads) as described in the manufacturer's protocol. Briefly, after harvest with trypsin-EDTA and phosphate buffered saline (PBS, pH 7.4) wash, cells (1 x 10 7 cells) were incubated with mouse anti-human CD24 monoclonal antibody (25 µl BCSCs in tumors, cell suspensions were prepared immediately after resection (<10 min). Tumor tissues (~60 mg) were cut into small pieces (<1 mm) and incubated with collagenase IV (500 units/ml; purchased from Sigma) in RPMI 1640 and incubated at 37°C for 2 hr with shaking (100 rpm). Further, cells were passed through a 70-μm cell strainer and washed twice with PBS.
Cellular ceramide glycosylation and GSL analysis-Ceramide glycosylation that is catalyzed in cells was analyzed as described previously (41) . Cells were grown 24 hr in 35-mm dishes (5 x 10 6 cells/dish) in 10% FBS RPMI-1640 medium and MBO-asGCS (100 nM) was introduced as described above. After 12 hr growth in 10% RPMI-1640 medium, cells were switched to 1% bovine serum albumin (BSA) RPMI-1640 medium containing 5 μM NBD C 6 -ceramide complexed to BSA (Invitrogen). After 2 hr incubation at 37°C, lipids were extracted and resolved on partisil high performance thin-layer chromatography (HPTLC) plates with fluorescent indicator (#4806-410; Whatman, Florham Park, NJ) in a solvent system containing chloroform/methanol/3.5N ammonium hydroxide (85:15:1, v/v/v) as described previously (41) . NBD C 6 -glucosylceramide and NBD C 6 -ceramide were identified using AlphaImager HP imaging system (Alpha Innotech, San Leandro, CA) and quantitated on a Synergy HT multidetection microplate reader. For quantification, calibration curves were established after TLC separation of NBD C 6 -ceramide (Invitrogen) and NBD C 6 -glucosylceramide (N-hexanol-NBDglucosylceramide; Matreya, Pleasant Gap, PA).
The endogenous GSL were extracted and analyzed as described previously (25, 42) . Briefly, cellular lipids were extracted with chloroform/methanol/water (1/1/1, v/v/v) from each cell line or subpopulation after vehicle or MBO-asGCS treatments. Extracted lipids were resuspended in chloroform-methanol (1/1, v/v) and applied to partisil HPTLC plates with fluorescent indicator. Lipids were resolved using the solvent systems of chloroform/methanol/Water (65/35/8, v/v/v) for GSLs. HPTLC plates were dipped for 10 sec in 0.02 % primuline (w/v; purchased from Sigma) in acetone/water (4/1, v/v). Fluorescence TLC profile graph was visualized under long-wave UV light (360 nm) and captured using AlphaImager HP system (Alpha Innotech). Neutral GSL qualimix (Matreya) were used as TLC standards. Globotriosylceramide (Gb3) of each sample was quantified by fluorescence intensity against the standard curve established using Gb3 lipids (Matreya) and normalized against cellular proteins.
MALDI-MS and MS analysis of GSLs-MALDI-MS profiling of permethylated GSLs was performed as described previously (43) . Briefly, the extracted GSLs (from 7.5 x 10 5 cells) were incubated with leech ceramide glycanase (50 mU/100 µl) (44) in 50 mM sodium acetate, pH 5.5 containing 0.1% sodium cholate, at 37 o C for 16 hr. The released glycans were separated from the ceramides and detergent by passing through a SepPak C18 cartridge (Waters, Milford, MA), and further desalted by a porous graphitized carbon solid-phase extraction cartridge. Permethylation was carried out by the NaOH/DMSO slurry method as described previously (45) . MALDI-MS analysis of the derivatives were carried out in positive-ion mode on a ABI 4700 MALDI-TOF/TOF mass spectrometer (Applied Biosystems, Foster City, CA) using 2',4',6'-trihydroxyacetophenone as the MALDI matrix. Gb3 mass intensity was normalized against cellular proteins of each sample.
Western blot analysis-After treatment, cells or tissue homogenates were lysed using NP40 cell lysis buffer (Biosource, Camarillo, CA, USA). The amount of total proteins was measured using a bicinchoninic acid (BCA) protein assay kit (Pierce, Rockford, IL). Equal amounts of detergent-soluble proteins (50 µg/lane) were resolved using 4-20% gradient SDS-PAGE (Invitrogen). After transferring, blots were blocked in 5% fat-free milk in PBS for 1 hr at 26 °C. Blots were then incubated with specific primary antibodies against GCS, FGF-2, Oct-4, CD44, cSrc, phosphorylated-cSrc, β-catenin and phosphorylated β-catenin (1:200 to 1:5000 dilution) overnight at 4ºC and then with respective horseradish peroxide-conjugated secondary antibodies (1:2500 dilution) for 1 hr at 26°C after washing. Proteins were detected using enzyme- Rockford, IL) as described previously (25, 30) . Endogenous GAPDH was used as a loading control for each sample. Tumor-bearing mice and treatments-All animal experiments were approved by the Institutional Animal Care and Use Committee, University of Louisiana at Monroe, and were handled in strict accordance with good animal practice as defined by NIH guidelines. Athymic nude mice (Foxn1 nu /Foxn1 + , 4-5 weeks, female) were purchased from Harlan (Indianapolis, IN) and maintained in the vivarium at University of Louisiana at Monroe. Animal studies were conducted as described previously (25, 36) . Statistical analysis-All experiments were conducted in triplicate and repeated two times. Data were analyzed by using Prism ver. 4 (GraphPad software, San Diego, CA) or SAS 9.2 (SAS system. Gary, NC) and presented as mean ± SD. Two-tailed Student's t tests were used to compare the continuous variables between groups and Fisher's extract test was used to compare the proportion between groups. All p<0.05 was considered statistically significant.
RESULTS
GCS is associated with BCSCs in drugresistance and tumorigenicity of cancer cells-
Different cancer cell lines display their own behavior in response to anticancer drugs and in tumor formation. In assessment of cell response to doxorubicin, we found that the half maximal inhibitory concentration (IC 50 ) value for doxorubicin in MCF-7/Dox cells was 30-fold (9.8 μM vs. 0.33 μM; p<0.001) higher than the MCF-7 breast adenocarcinoma cells or human MCF-12A mammary epithelial cells (Fig. 1A) . These results are consistent with previous reports, as MCF-7/Dox cells, which have been selected with doxorubicin culture from MCF-7 cells, are resistant to doxorubicin (35) . Furthermore, MBOasGCS treatment (100 nM) to silence GCS expression (36) in the present study significantly decreased the IC 50 for doxorubicin by 13-fold (9.8 μM vs. 0.75 μM; p<0.001) in MCF-7/Dox cells (Fig. 1A) . Examining colony formation in soft agar we found that MCF-7/Dox cells formed 160% more colonies (9,325 cells vs. 5,715 cells; p<0.001) than MCF-7 cells or MCF-12A cells (Fig. 1B) Fig. 2A, 2B ). Silencing of GCS using MBOasGCS significantly reduced the BCSCs to 42% (1.3% vs. 3.1% of cancer cells; p<0.001) in MCF-7/Dox cells ( Fig. 2A, 2B ).
Ceramide glycosylation catalyzed by GCS is crucial for tumor formation-To determine if ceramide glycosylation plays a role in modulating BCSCs, we examined the correlation of GCS expression, ceramide glycosylation and endogenous GSLs with BCSCs. Western blotting showed that GCS levels in MCF-7/Dox cells weresilencing of GCS using MBO-asGCS substantially reduced GCS to 40% in MCF-7/Dox cells (Fig.  3A) . Interestingly, the expression of fibroblast growth factor 2 (FGF-2) and Oct-4, which are required for the proliferation of normal stem cells and CSCs (2, 47, 48) , was substantially increased with levels of GCS protein in these cells (Fig. 3A) . Consistent with protein level, GCS activity in MCF-7/Dox cells was 2-fold (26 pmol/mg vs. 13 pmol/mg) higher than MCF-7 cells or MCF-12A cells (Fig. 3B) . The GSL profiling analyzed by HPTLC indicated that GSLs, particularly of Gb3 in MCF-7/Dox cells were 2-fold (32.6 vs.15.4 ng/mg; p<0.001) greater than MCF-7 and 4-fold (32.6 vs. 8.2 ng/mg; p<0.001) greater than MCF-12A cells (Fig. 3C) . Silencing of GCS with MBOasGCS decreased GSLs, and the Gb3 was reduced to 28% (9.1 ng vs. 32.6 ng/mg; p<0.001) in MCF-7/Dox cells (Fig. 3C ). To verify these findings, GSLs further profiled using MALDI-MS and MS/MS analysis (43) . The Gb3 levels in MCF-/Dox cells was 250% higher than in MCF-7 cells (10179 vs. 4139 in absolute height; p<0.001) and 347% higher than in MCF-12A cells (10179 vs. 2833 in absolute height; p<0.001) (Fig. 3D, 3E-3F ). MBO-asGCS treatment reduced the Gb3 to 33% (3349 vs. 10179 in absolute height; p<0.001) in MCF-7/Dox cells (Fig. 3D) . We further examined whether or not GCS itself is able to induce BCSCs in MCF-7 cells. As shown in MBO-asGCS treatment decreased BCSCs to 43% (2.0% vs. 4.6% tumor cells; p<0.001) (Fig. 4B) 5A) . These results further were confirmed by tumor sphere assay (Fig. 5A bottom) . Furthermore, the tumorigenicity of BCSCs and CD44 -/CD24 -cells were examined in athymic nude mice. It was found that BCSCs formed significantly more tumors and the tumors were bigger than the non-stem cell subset (CD44 -/CD24 -) ( Table 1 , Fig. 5B ). The tumor incident detected in the BCSC group (1 x 10 5 cells/mouse inoculation; 12/12 mice) is statistically significant, 6-fold higher (p<0.0071) than CD44 + /CD24 -group (1/6 mice). Tumors from BCSCs grew aggressively and were 6-fold larger than the nonstem cell subset (1,858 vs. 274 mm 3 ; p<0.001) (Fig. 5B) . Moreover, lung metastases were detected in mice injected with BCSCs (2/12), but not in mice inoculated with CD44 -/CD24 -cells, as indicated in the H&E staining of lung section (Fig.  5B bottom panel) . However, the difference of metastasis incidence was not significant (p<0.99) between the two groups, due to small sample size.
It has been reported lately that CD44 (Fig. 6A) . Profiling of GSLs using HPTLC indicated that the levels of GSLs were consistent with the alteration of GCS activities in BCSCs, non-stem cell subset and BCSCs treated with MBO-asGCS (Fig. 6A, 6B) . Markedly, Gb3 levels in BCSCs were significantly higher than in non-stem cell subset (CD44 -/CD24 -) and MBO-asGCS treatment reduced Gb3 to 37% (46 vs. 17 ng/mg; p<0.001) in BCSCs (Fig. 6B) . These results were further confirmed by findings using MALDI-MS and MS/MS analysis. As shown in Fig. 6C, 6D , MBO-asGCS treatment significantly reduced Gb3 level in BCSCs to 50% (15816 vs. 31430 in absolute height; p<0.001). Together, these findings indicate enhanced ceramide glycosylation is a unique characteristic of BCSCs and it plays a crucial role in maintaining the stemness of BCSCs.
cSrc/β-catenin signaling modulated by GCS is essential for BCSCs-It has been reported that Wnt/β-catenin signaling is critical for the selfrenewal of normal mammary epithelial stem cells and BCSCs (17, 18, 50, 51) . Globo-series of GSLs can mediate Wnt/β-catenin signaling and cell functions (25, 52, 53) . To elucidate how GSLs modulate BCSCs, a stepwise-inhibition approach was employed to examine the effects of ceramide glycosylation on BCSC stemness. As shown in Fig  7, the protein levels of CD44, FGF-2, Oct-4, phosphorylated cSrc and β-catenin (active form) were substantially increased in BCSCs, as compared to non-stem cells (CD44 -/CD24 -); suppression of ceramide glycosylation by MBOasGCS (100 nM) substantially repressed the protein expression of CD44, FGF-2 and Oct-4, accompanied by a decrease of phosphorylated cSrc and β-catenin (active form) in BCSCs (CD44 + /ESA + /CD24 -) (Fig.  7A,  7B ). Consequently, MBO-asGCS decreased BCSCs to 30% in MCF-7/Dox cells (Fig. 7C) . FH535 can specifically inhibit β-catenin recruitment of transcription factors and regulation of gene expression (25, 54, 55) . We found that FH535 treatments (5 μM) repressed the protein expression of CD44, FGF-2 and Oct-4 by approximately 3-fold in BCSCs, and thus decreased BCSCs to 41% in MCF-7/Dox cells (Fig. 7A, 7C ). It has been reported that pyrazolo pyrimidine (PP2) can inhibit cSrc phosphorylation (25, 56, 57) . In this study, PP2 treatments (5 μM) significantly decreased the levels of phosphorylated cSrc and reduced the level of β-catenin to 7% (0.9 vs. 13.0 β-catenin/pβ-catenin; p<0.001) in BCSCs (Fig.  7B) . Consistently, PP2 treatment decreased BCSCs to 33% in MCF-7/Dox cells (Fig. 7C) . Together, these findings strongly suggest that ceramide glycosylation activates cSrc and β-catenin signaling pathway, and mediates the expression of CD44, FGF-2 and Oct-4 to maintain BCSCs.
DISCUSSION
Our results clearly indicate that ceramide glycosylation catalyzed by GCS is important for CSCs in drug resistance and tumorigenesis. BCSCs have been identified with surface markers, such as CD44 + /ESA + /CD24 -, in established breast cancer cell lines and in tumor specimens (3, 5, 6, 46) . In addition to tumorigenesis, the accumulated BCSCs in tumors drive tumor progression to disseminated metastasis and poorresponse to chemotherapy (8, 10, 58) . Among human breast cancer cell lines, the tumorigenesis and drug resistance are reported highly associated with the numbers of BCSCs (5, 6, 59) . In the present study, MCF-7/Dox cells that have 3-fold more BCSCs displayed marked resistance to doxorubicin and were aggressive in tumorigenesis (Fig. 1, 2, 4) . Despite GCS overexpression in metastatic breast tumors and causing drug resistance (31, 33) , there is no clear experimental evidence linking these to CSCs. Ceramide glycosylation by GCS found in the present study was correlated well with BCSCs as well as their tumorous property in drug resistance and tumorigenicity. MCF-7/Dox cells overexpressed GCS protein and produced 2-fold more Gb3 following enhanced ceramide glycosylation, as compared to MCF-7 breast cancer cells. In contrast, the levels of GCS protein and Gb3, which were consistent with the BCSC numbers, were substantially lower in normal MCF-12A mammary epithelial cells (Fig. 3) . Disruption of ceramide glycosylation by silencing of GCS decreased BCSCs in cultured cells and in tumors generated from MCF-7/Dox cells (Fig. 2, Fig. 4) ; consequently, silencing of GCS reversed drug resistance and eliminated tumorigenesis. These results together indicate that enhanced ceramide glycosylation, due to GCS overexpression is essential for BCSCs remaining drug resistance and tumorigenicity.
With direct evidence, the present study demonstrated that globo-series GSLs play a crucial role in maintaining CSCs. Among GSLs synthesized after ceramide glycosylation, globopentosylceramide (Gb5, Galβ3GalNAcβGalβ4Glcβ1Cer) and monosialyl globopentosylceramide (MSGb5, Siaα2,3Galβ3GalNAcβGalβ4Glcβ1Cer), which are generated from Gb3 and recognized as stage specific embryonic antigen-3 and -4 (SSEA-3, -4), are broadly used as markers to characterize undifferentiated human embryonic stem cells including isolated, derived, and induced pluripotent stem cells (20) (21) (22) 60, 61) . Gb5 and other globo-series GSLs are synthesized by a serial glycosylation of ceramide catalyzed by GCS, lactosylceramide synthase, Gb3 synthase, and Gb5 synthase, but GCS is the first ratelimiting enzyme for their synthesis in mammalian cells (62, 63) . GSLs play important roles in ESCs, as homozygous knockout of ugcg in mouse prevents the development and differentiation of the gastrulating embryo by massive apoptosis largely in the ectodermal layer (27) . Deletion of GSLs by using GCS inhibitor (1-phenyl-2-decanoylamino-3-morpholino-1-propanol, PDMP), previous study indicates that Gb5 and MSGb5 do not play critical functional roles in maintaining the pluripotency of human ESCs, even though their expression clearly marks undifferentiated ESCs (64). Gb5 and Glob H (Fucα1-2Galβ1-3GalNacβ1-3Galα1-4Galβ1-4Glcβ1) generated from Gb5 by fucosyltransferase, are overexpressed on breast cancers and other epithelial cell tumors, such as colon, ovarian, gastric pancreatic, lung, and prostate cancers (28, 65, 66) . However, Gb5 and Globo H, which are examined by flow cytometry analysis are expressed with no significant difference between BCSCs (CD45 -/CD24 -/CD44 + ) and non-BCSCs (CD45 -/CD24 + /CD44 + , CD45 -/CD24 -/CD44 -) sorted from tumor specimens of breast cancer patients (66) . To clarify the role of GSLs in CSCs, we employed direct approaches to assess GCS protein, ceramide glycosylation, Gb3 by mass spectrometry, BCSC numbers and their tumorous properties of BCSCs at the present of GCS silencing. Non-stem cell subset (CD44 -/CD24 -) presented much lower tumorigenicity and GCS activity than in any other populations (Fig.  5) . BCSCs (CD44 + /ESA -/CD24 -) overexpressed GCS and produced more Gb3. Importantly, disruption of ceramide glycosylation by silencing of GCS inhibited Gb3 in BCSCs (CD44 + /ESA -/CD24 -) and consequently it eradicated BCSCs, displaying in tumor formation and tumor progression (Fig. 5, Fig. 6 ).
Ceramide glycosylation by GCS is a unique process by which CSCs maintain their tumorous stemness. Ceramide glycosylation, which is known for reducing cellular ceramide biochemically and protecting cell from ceramideinduced apoptosis, can endow CSC resistance to cytotoxins and anticancer drugs. It has been reported that CSCs (CD55 hi ) are high tolerance to ceramide-induced apoptosis, and this resistance is attributed to abundance of sphingomyelin synthase 1 that can converts ceramide to sphingomyelin (67) . Because GCS level is higher in BCSCs vs. lower in bone marrow stem cells, doxorubicin can enhance BCSC number and decrease the number of bone marrow stem cells (68) . Numerous studies show that GSLs, such as Gb5 and MSGb5 as markers of stem cells, however, no cuttingevidence links their expression to a role in pluripotency, and their molecular functions remain unclear. Gb5 and MSGb5, as markers of human ESCs, disappear with differentiation (64, 69) . Mass spectrometry analysis that can distinguish glycans shows a switching of the core structures of glycosphingolipids from globo-and lacto-to ganglio-series when human ESCs differentiate into embryoid body outgrowth with three germ layers (69) . Recent study shows that ganglioside GD2 can be used as a marker to identify CSCs (GD2 + ) from breast cancer cell lines and patient samples, and interference with GD3 synthase can reduce CSC population and CSC-associated properties (70) . The present study found GCS and Gb3 overproduced in BCSCs, not normal adult stem cells, such as mammary epithelial stem cells (Fig.  3) and bone marrow stem cells reported by another study (68) . It is not clear by which molecular mechanism CSCs regain ability in ceramide glycosylation that exists in ESCs. We now know that ceramide generated in cells exposed to doxorubicin can activate GCS promoter and upregulate its expression (38) .
A major contribution of present work is that we identified the role of Gb3 in maintaining stem property of BCSCs. It has been reported that Gb3 (CD77), a precursor of Gb5 is associated with Src family Yes kinase on GSL-enriched microdomains (GEM) (25, 71) . Gb3 can modulate cSrc kinase in GEM and upregulate mdr1 expression through β-catenin signaling (25) . Wnt/β-catenin signaling maintains hematopoietic stem cells and neuronal stem cells, and the epithelial to mesenchymal transition (EMT) for BCSCs (72) ; Wnt inhibitors can reduce the size of tumor spheres and selfrenewal in prostate cancer stem cells (73) . FGF-2 is critical for the self-renewal and maintenance of normal and cancer stem cells (47, 48) and Oct-4 is a transcription factor that is involved in maintaining the pluripotency of ESCs (74) and BCSCs (75, 76) . This study has found that the levels of GCS, Gb3, phosphorylated cSrc, β-catenin, FGF-2, and Oct-4 are substantially higher in BCSCs (Fig. 7) . Stepwise inhibition of GCS, cSrc kinases and β-catenin indicates these molecules are critical for the maintenance of BCSCs (Fig. 7) . Although stem cell factors including β-catenin, FGF-2, Oct-4, and CD44 are involved in regulating stemness of either normal stem cells or CSCs, this study demonstrates that GSLs in BCSCs activate cSrc/β-catenin signaling and upregulate these factors to maintain BCSCs selectively. In addition to insight regulating stemness of stem cells, this finding opens the possibility of, disrupting ceramide glycosylation or GSL synthesis to target CSCs specifically. -subset; **, p<0.001 compared with the FGF-2/GAPDH ratio of BCSC. (B) cSrc phosphorylation mediates GCS effect on enhancing β-catenin in BCSCs. Equal amounts of detergent-soluble proteins (50 μg/lane) were resolved by 4-20% SDS-PAGE and immunoblotted with anti-GCS, cSrc, p-cSrc, p-β-catenin, β-catenin and GAPDH antibodies. BCSC+PP2, BCSCs sorted from MCF-7/Dox cells treated with PP2 (cSrc kinase inhibitor, 5 μM for 24 hr); p-cSrc, phosphorylated cSrc; p-β-catenin, phosphorylated β-catenin. *, p<0.001 compared with the β-catenin/GAPDH ratio of CD44 -/CD24 -subset; **, p<0.001 compared with the β-catenin/GAPDH ratio of BCSCs. (C) Effects of inhibitions of GCS, cSrc kinases and β-catenin on BCSCs. BCSCs were analyzed following MCF-7/Dox cells treated with MBO-asGCS (100 nM, 7 days; Dox/asGCS), PP2 (5 μM, 24 hr; Dox/PP2) and FH535 (5 μM, 24 hr; Dox/FH535). *, p<0.001 compared with vehicle control of MCF-7/Dox cells. 
